California State Teachers Retirement System Buys 59,967,294 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Posted by Brian Himes on Sep 8th, 2026

California State Teachers Retirement System grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 30,461.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,164,157 shares of the biopharmaceutical company’s stock after buying an additional 59,967,294 shares during the period. California State Teachers Retirement System owned 44.96% of Alnylam Pharmaceuticals worth $18,111,216,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. iA Global Asset Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 979.5% during the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after purchasing an additional 16,133 shares during the period. SCS Capital Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $34,784,000. Hsbc Holdings PLC boosted its holdings in Alnylam Pharmaceuticals by 22.6% in the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after buying an additional 16,503 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth $50,773,000. Finally, Keystone Investors PTE Ltd. purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth $3,531,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $266.11 on Tuesday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $35.61 billion, a P/E ratio of 49.46 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $495.55. The business’s 50-day moving average is $258.70 and its 200 day moving average is $290.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same period in the prior year, the company earned ($0.51) earnings per share. The firm’s revenue was up 66.9% on a year-over-year basis. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the topic of several research analyst reports. TD Cowen restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Citigroup dropped their price objective on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Bank of America cut their target price on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Sanford C. Bernstein reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Finally, Oppenheimer lowered their price target on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $386.14.

View Our Latest Stock Analysis on ALNY

About Alnylam Pharmaceuticals

(Free Report)

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.